MedTrace Logo

VTE Prevention Following Total Hip and Knee Arthroplasty

NCT04075240 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5400

Last updated 2024-02-07

No results posted yet for this study

Summary

Consented patients undergoing elective total hip and total knee arthroplasty will be randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of venous thromboembolism.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Rivaroxaban 10 MG and acetylsalicylic acid 81 mg

Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)

DRUG

acetylsalicylic acid 81 mg

Starting post op, aspirin for 9 days for TKA and 30 days for THA

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Nova Scotia Health Authority

    collaborator OTHER

  • Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

    collaborator NETWORK

  • Sudeep Shivakumar

    lead OTHER

Principal Investigators

  • Sudeep P Shivakumar, MD · Dalhousie University/Nova Scotia Health Authority

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-04
Primary Completion
2025-12-31
Completion
2026-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04075240 on ClinicalTrials.gov